Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα.

Thrombosis and haemostasis - 1 Jan 2020

van Doorn Peter, Rosing Jan, Campello Elena, Middeldorp Saskia, Simioni Paolo, Meijers Joost C M, Hackeng Tilman M, Castoldi Elisabetta

Abstract excerpt

BACKGROUND: Factor V (FV) is proteolytically activated to FVa, which assembles with FXa in the prothrombinase complex. The C-terminus of tissue factor pathway inhibitor-α (TFPIα) inhibits both the activation and the prothrombinase activity of FV(a), but the pathophysiological relevance of this anticoagulant mechanism is unknown. FV Leiden (FVL) is less susceptible to inhibition by TFPIα, while overexpression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation
Share to Blood Coagulation Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Coagulation Tests

Share to Factor V

Share to Factor Xa

Share to Lipoproteins

Share to Peptide Fragments

Share to Proteolysis

Source

Identifiers

PMID: 31705518
DOI: 10.1055/s-0039-1700516

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα.PMID 31705518Read ↗

Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders.Semantic proximity Read ↗

The M358R variant of α(1)-proteinase inhibitor inhibits coagulation factor VIIa.Semantic proximity Read ↗

Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2.Semantic proximity Read ↗

Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes.Semantic proximity Read ↗

A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function.Semantic proximity Read ↗

Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.Semantic proximity Read ↗

The anticoagulant function of coagulation factor V.Semantic proximity Read ↗

The common VTE-protective G haplotype of F5 increases factor V-short, TFPI function, and risk of bleeding.Semantic proximity Read ↗

A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates.Semantic proximity Read ↗

Genetic determinants of tissue factor pathway inhibitor plasma levels.Semantic proximity Read ↗

New insights into the biology of tissue factor pathway inhibitor.Semantic proximity Read ↗

Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besançon).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.